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This report presents the recommendations to the ISSCR leadership from the industry panel session at the
2009 annual conference. The seven recommendations address core issues essential for the promotion of
stem cell and regenerative medicine translation and commercialization.Today we are at the start of a new healthcare sector. Not one
based on therapies that simply manage symptoms and amelio-
rate disease, but one that is focused on the replacement and
regeneration of cells, tissue, and organs in order to restore
normal function (Mason and Dunnill, 2008a). The ultimate goal
is cure. However, to achieve this target will undoubtedly require
the research and commercial communities to reach out to
one another in order to facilitate the necessary interaction,
understanding, and mutual trust that are paramount. All the
regenerative medicine stakeholders need to be able to integrate
seamlessly if we are to efficiently deliver these advanced stem
cell-based therapies into routine clinical practice. Although the
research community has increasingly become better networked
together through organizations such as the ISSCR, unfortunately
to date, linkages between the academic and the presently
nascent commercial world are still to be properly developed.
This is mainly due to the stem cell science only now beginning
to adequately mature to the level of producing practical applica-
tions (Marshak, 2007). The ISSCR leadership recognizes the
important role of industry in the development of therapeutic
and diagnostic applications and has been addressing the issue
with a number of initiatives including establishing an industry
committee in 2005, Industry Wednesday Symposia, and ‘‘Meet
the Expert’’ sessions at the annual meeting and resources, for
example, ‘‘Guidelines for the Clinical Translation of Stem Cells’’
(Hyun et al., 2008; Marshak, 2007). However, the ISSCR leader-
ship also recognizes that additional activities are required if
the organization is to fulfill its responsibility to embrace the clin-
ical and commercial translation of the whole spectrum of stem
cell-based therapies, tools, and targets including cell and
tissue-engineered therapies, as well as drug discovery and
development.
In July 2008, Nancy Witty (Executive Director, ISSCR) ap-
proached Chris Mason (University College London) to organize
and moderate a lunchtime panel session at the 2009 annual
conference in Barcelona. For over a decade, Mason has been
firmly committed to bringing together academics, clinicians,
and commerce in order to deliver safe, effective, and affordable
therapies for routine clinical use. The overall aim of the proposed
panel session was to produce a set of recommendations to the
ISSCR leadership that would further bring together the academic
and commercial communities. It was agreed that the expert
panel should span all the current commercial areas including
cell and tissue engineering, cell types, and organizations(pharma/biotech/regenerative medicine). Furthermore, at least
onemember of the ISSCR Industry Committeemust be included.
Short biographies of the panel members (Table 1) can be found in
the Supplemental Data available online. Interestingly, the major-
ity of the panellists had already participated in earlier discussions
on the topic of promoting translation and commercialization and
were known to be both knowledgeable and extremely positive
with respect to facilitating essential dialog and action. It is impor-
tant to note that being a member of ISSCR was definitely not
a prerequisite for participation. In setting the agenda for the
panel session, a detailed search of the literature was undertaken
before a number of conference calls between members of the
panel and ISSCR staff were arranged. It soon became apparent
that there were three overarching issues which the panel session
needed to address:
1. What are the challenges to the scientific community in
promoting clinical translation and commercialization?
2. How are the links and bridges best built and sustained?
3. How does the ISSCR best get involved?
For the members of the panel who were not significantly
involved with the ISSCR (MacKay, Mason, and McKernan), it
quickly became apparent the very significant role that the ISSCR
could potentially have in promoting translation and commercial-
ization through leveraging its core competencies including:
established infrastructure, international reputation and brand,
global reach and, most importantly, independence (Witty, 2007).
Therewere a number of relevant questions raised during the tele-
phone conference calls including:
 Why are big pharma not engaged with ISSCR?
 Why are tissue-engineering companies likewise not
engaged with ISSCR?
 What is the scope of regenerative medicine with respect to
ISSCR and translation and commercialization? (Recombi-
nant erythropoietin and bone morphogenic protein both
work to regenerate in the broadest sense but are more
closely aligned to the pharma/biotech than regenerative
medicine industry with its living cells as products
approach.)
However, two overriding questions that kept coming up with
respect to the promotion of translation and commercialization
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Moderator
Chris Mason, PhD, FRCS Professor of Regenerative Medicine Bioprocessing, Advanced
Centre for Biochemical Engineering, University College London
London, UK
Panel Members
Gregory A. Bonfiglio, JD Managing Partner, Proteus Venture Partners Palo Alto, CA, USA
Jane S. Lebkowski, PhD Senior Vice President and Chief Scientific Officer, Regenerative
Medicine at Geron Corp. & Co-chair, ISSCR Industry Committee
Menlo Park, CA, USA
Geoff MacKay President and Chief Executive Officer, Organogenesis, Inc. Canton, MA, USA
Ruth M. McKernan, PhD Vice President and Chief Scientific Officer, Pfizer Regenerative
Medicine, Pfizer Inc.
Cambridge, UK, and
Cambridge, MA, USA What are the major challenges that ISSCR could address
given its role and position in the sector?
 How can these major challenges be addressed?
Panel Session
The date of the panel was set for the lunchtime of the final day of
the ISSCRconference inBarcelona.Approximately 200audience
participants including 40 of the ISSCR leadership, former presi-
dents, and the new president, Irving Weissman, were expected
to attend. It was therefore decided that in order to introduce the
entire topic and to establish a common baseline, the panel would
begin by setting the scene and describing the journey that
a potential product would take from the bench to routine clinical
practice. The route described started at the laboratory and pro-
gressed through a new spin-out company onto a regenerative
medicine company in clinical trials, then to an established com-
pany with multimillion-dollar revenues, and finally, big pharma.
A process not unfamiliar to biopharmaceutical compounds but
because the process and the final product are totally inseparable,
unlike for a molecular drug, the level of integration and overall
complexity is a least an order of magnitude more challenging.
The main purpose of the brief talks was to expose the members
of the audience to a whole new world outside of the laboratory
and to debunk the many myths and misconceptions about
commercial translation. Each of the panelists gave a very brief
introduction to themselves and their companies (summarized in
theSupplementalData) followedby themain translational hurdles
directly related to their specific sector of the industry.
The first presenter was Greg Bonfiglio of Proteus Venture Part-
ners and an ISSCR Industry Committee member. As a venture
capitalist involved in every aspect of stem cells and regenerative
medicine, including funding spin-out companies, he was ideally
positioned to set the overall scene. This included the history of
the fledgling industry since its origins in the 1980s at MIT, its
meteoric rise based on unrealistic expectations, collapse in
2001 and re-emergence as Regenerative Medicine 2.0 as an
industry based firmly on commercial translation and not on
science and basic discovery (Mason, 2007). Deploying
a bespoke regenerative medicine version of the Gartner Hype
Cycle (a graphical representation of the maturity, adoption, and
business application of a step-change technology), Bonfiglio
finished with the upbeat prediction that the current fledgling
regenerative medicine industry was now all set to substantially
grow into a sustainable new healthcare industrial sector.
However, he warned that funding in the short term was severely380 Cell Stem Cell 5, 379–384, October 2, 2009 ª2009 ISSCRrestricted as a result of the global financial crisis and that this
would have a direct impact on potential start-up and other pre-
revenue regenerative medicine companies.
Jane Lebkowski of the Geron Corporation and Co-chair of the
ISSCR Industry Committee continued by speaking on the chal-
lenges for regenerative medicine companies in entering clinical
trials including preclinical research and development, and the
filing of a successful Investigational New Drug Application
(IND) with the FDA for a stem cell-based therapy. In particular,
Lebkowski discussed the significance for a company in choosing
an appropriate disease indication suitable of being successfully
commercialized, the absolute necessity for scalable GMP
manufacturing and devising appropriate protocols for the future
clinical trials. The imperative to carefully balance financial
resources and milestones was also addressed. Lebkowski
closed by briefly discussing late-stage clinical trials, contract
manufacturing organizations (CMOs) versus in-house manufac-
ture, and storage and distribution.
Following on, Geoff MacKay of Organogenesis, Inc., started
by highlighting the origin of his company as a leading tissue-
engineering pioneer that rode the tide of unrealistic expectations
fueled by a deluge of hundreds of millions of dollar of investment
capital only to file for Chapter 11 bankruptcy in 2001. The re-
emergence of a commercially viable organization under MacK-
ay’s leadership was based upon an experienced and capable
management team coupled to solid pragmatism. MacKay then
focused on key areas including the supply chain and distribution,
reimbursement, intellectual property rights (IPR), and regulation.
He reported that over 250,000 patients have now been treated
with Apligraf (tissue-engineered skin). Only with considerable
infrastructure and logistics planning could this feat be achieved
with a living cell-based product that takes 3 weeks to grow
and has a similar length shelf life. MacKay also noted that the
Centers for Medicare & Medicaid Services (CMS) and private
payers are now perfectly structured to reimburse cell therapies,
a situation not previously enjoyed by the original industry
pioneers. In closing,MacKay identified two areas of global signif-
icance. The first related to the pressing requirement for interna-
tional regulatory harmonization and the present lack of global
regenerativemedicine products. This is due to the immense diffi-
culty of adhering to diverse standards across geographies in
preclinical and clinical dossiers as well as process improvement
methodologies. The second issue was the emphasis that global
recruitment of key staff was essential if a company wanted to
assemble the very best team.
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tive Medicine. It is widely acknowledged that for stem cells
and regenerative medicine therapies to realize their full potential,
i.e., be safe, effective, and affordable such that they are routinely
deployed in routine clinical practice, big pharma needs to
become fully involved. McKernan started with the establishment
of Pfizer Regenerative Medicine, a $100M-funded Pfizer Division
based in Cambridge, UK, and Cambridge, MA, USA, focused
exclusively on therapies. She then broadened her talk to include
the wider pharma sector and its interests and goals with respect
to stem cell technologies. The topics of tools, targets, and ther-
apeutics were discussed including McKernan’s involvement in
chairing Stem Cell for Safer Medicines (a UK Government/
private funded toxicology program). McKernan pointed out that
the drivers for big pharma included the much greater financial
potential of therapeutic applications rather than diagnostic tests.
Using Pfizer’s recent investment in the UCL Institute of Ophthal-
mology project for the prevention of age-related macular degen-
eration deploying embryonic stem cell-based therapy as an
example, McKernan went on to discuss the main issues that
big pharma really cares about. The number-one selection crite-
rion is efficacy with preclinical and ideally clinical proof of
concept data. Interestingly, the type of starting cell was not
a significant issue; however, the disease indication (but not inci-
dence) and scalability of manufacture were also highly impor-
tant. McKernan concurred with MacKay on the issues of the
requirement for a defensible intellectual property position, the
intellectual property thicket, freedom to operate, and unrealistic
intellectual property valuations in addition to the need for patent
pooling. Overall, McKernan stressed the importance of under-
standing that big pharma is ‘‘not a bottomless pit’’ of money
and that for big pharma to come on-board required the potential
to deliver high volume therapies that are either cell based or
small molecules/biologicals that modify cell fate in vivo.
This initial round of short presentations was followed by the
first question-and-answer session. The members of the panel
next went on to give very brief overviews from their industry-
sector-specific perspective of how links and sustainable bridges
can best be built between the academics and commercial com-
munities. Again, this was followed by a question-and-answer
session. Finally, Lebkowski summed up the major conclusions
of all the debate and discussion to date including the panel’s
conference calls, the panelists’ presentations, and the views
and comments of the audience participants.
Recommendations to the ISSCR Leadership
Seven specific recommendations were made to the ISSCR lead-
ership in order to promote translation and commercialization
(see Table 2). The background, underlying reasoning and related
discussion from all the activities is below. The list is not indicative
of the order of priority.
The recommendations to the ISSCR leadership embraceall the
stakeholder groups and specifically the ISSCR members,
industry, and the general public. Furthermore, the recommenda-
tions took into account the need to develop tangible outcomes
that couldbeachievedwithin 1–2 years and thus relatively quickly
provide a solid foundation to further build upon. Focus and prag-
matism was therefore at the forefront. The panel recognizes that
the commitment from the ISSCR includes the need for sponsor-ship and coordination of the various activities. Adequate and
ongoing resources will therefore be required if the recommenda-
tions are to have real impact in the medium to long-term future.
Recommendations 1–4: Commercially orientated
education provisions for ISSCR members
The first four recommendations stem from the underlying
requirement to fill a large unmet need in the training of scientists.
In particular, scientists need to be trained in the core competen-
cies required within academia so that they can appreciate the
challenges of clinical and commercial translation and explore
opportunities for alternative stem cell-related careers outside
of the laboratory. As the science travels from Petri dish to the
factory, a shortage of appropriately skilled people in all areas
of stem cell commercialization including sales and marketing,
manufacturing, and management will be a significant bottleneck
unless we start planning now. In addition, because the tech-
nology is verymuch a new entity, the same is true for all the asso-
ciated service industries; for example, patent lawyers, storage
and distribution companies, and contract clinical-trial organiza-
tions to name just a few. The need therefore for ongoing training
and education in academia was highlighted by all the panelists
as being vital for the efficient translation of stem cell science
into commercial products. For example, MacKay illustrated the
enormity of the challenge of scaling a laboratory bench approach
after the FDA regulatory approval had been granted and when
any significant changes to manufacturing would require at the
very least clinical bridging studies that are both expensive and
time consuming. It is far better to engineer scalability into the
initial basic science phase, and yet very few scientists are aware
that such a relatively minor change in their research perspective
at this point could make the difference between commercial
success and failure.
Table 2. Specific Recommendations to ISSCR Leadership
to Promote Translation and Commercialization
ISSCR to Sponsor and Coordinate Activities (not in order of priority)
1. Workshops and training sessions to expose and educate
scientists to alternative career opportunities in the
biotechnology, pharmaceutical, and scientific tools industries,
e.g., quality affairs, legal, intellectual property, manufacturing,
regulatory, clinical development, and project management
opportunities.
2. Workshops and/or training sessions that include regulatory
authorities and/or experts to provide simulated case studies in
the development of stem cell-based products.
3. Workshops and training on intellectual property rights (IPR)
including freedom-to-operate analyses.
4. Workshops, training sessions, or other educational materials
on biotechnology and pharmaceutical industries on the
transfer of technology from academia to industry.
5. Provide public informational services on global stem cell
clinical trials and provide checklist of questions for patients to
ask about clinical trials so they can make informed choices.
6. Establish a list of potential experts in different fields that may
be of assistance to scientists newly involved in translational
activities.
7. Provide opportunities for a coordinated academia/industry
voice in areas of policy development.Cell Stem Cell 5, 379–384, October 2, 2009 ª2009 ISSCR 381
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training sessions will require bespoke educational material that
will need to evolve with these new ISSCR activities. The work-
shops would need to involve fictitious case studies in order to
allow the participants to systematically examine various transla-
tional and commercial scenarios while interacting with experts
and colleagues. The educational activities also need to be easily
updatable and scalable and therefore, in time, capable of being
rolled out to the entire ISSCR membership regardless of their
geographical location.
Recommendation 1: Workshops and training sessions
to expose and educate scientists to alternative career
opportunities in the biotechnology, pharmaceutical,
and scientific tools industries
The panel session identified the requirement for workshops and
training sessions to enable scientists to be aware of, and to be
able to properly evaluate, alternative career opportunities across
the entire spectrum of stem cell-related activities. This would
include not just research posts in biotech, big pharma, and the
scientific tools industry but also the myriad of other employment
opportunities including quality affairs, legal, intellectual property,
manufacturing, regulatory, clinical development, and project
management—all employment opportunities that are vital in
the efficient transfer of stem cell discoveries into routine clinical
practice. The insight gained at the bench is invaluable to these
careers. Overall, this will be a win-win for both researchers
who wish to venture outside of the laboratory as well as the
industry that will be able to recruit individuals with an under-
standing of the underlying technology.
Recommendation 2: Workshops and/or training
sessions that include regulatory authorities
and/or experts to provide simulated case studies
in the development of stem cell-based products
Healthcare regulatory issues are both complex and constantly
evolving especially when they need to keep pace with disruptive
technologies such as stem cell-based therapies.Workshops and
training involving both regulators (e.g., FDA and EMEA) and other
experts (e.g., quality assurance and quality control profes-
sionals) could help scientists and regulators better understand
each other’s perspectives and thus build vital bridges between
the communities. Key topics would include good manufacturing
practice (GMP) manufacture and the clinical-trial process. The
overall aim would be to enable researchers to navigate a path
through what many perceive as an impenetrable maze rather
than a two-way dialog between themselves and the regulators.
The FDA has already set a precedent by holding a one-off
open committee discussion in April 2008, ‘‘Cellular Therapies
Derived from Human Embryonic Stem Cells Scientific Consider-
ations for Pre-Clinical Safety Testing,’’ which involved principally
industrialists (including Lebkowski). However, all felt that the
discussion would have had an even greater value if the ISSCR
broadening out the discussion to academia.
Recommendation 3: Workshops and training
on intellectual property rights including
freedom-to-operate analyses
Throughout the panel session, the themes of intellectual prop-
erty rights (IPR) and transfer of technology from academia to
industry kept recurring. The present ‘‘patent thicket,’’ the neces-
sity for defensible IPR and freedom to operate are vexing issues382 Cell Stem Cell 5, 379–384, October 2, 2009 ª2009 ISSCRboth to venture capitalists keen to invest in the space and to big
pharma. All the panelists expressed their significant concerns
about this area. Indeed, McKernan voiced the need for a mecha-
nism for ‘‘patent pooling’’ in order to simplify the due diligence
process for venture capitalist and strategic investors as well as
for big pharma wishing to adopt the particular invention or dis-
covery. Part of the difficulty is the general lack of understanding
or the misunderstanding over the filing, use, and perceived value
of patents. The challenge is further exacerbated by the high
level of ‘‘trade secrets,’’ i.e., ‘‘know-how’’ rather than tangible
patents, that presently cloak the entire sector. It was felt that
workshops and training opportunities for ISSCRmembers would
arm the researcher with better insight into the world of intellec-
tual property and facilitate the creation of more appropriate
and better-filed patents. The workshops would need to involve
all the key intellectual property professionals including patent
agents and business units of the universities and institutes as
well as pharma patent lawyers so that the necessary compre-
hensive advice and future contacts could be provided.
Recommendation 4: Workshops, training sessions,
or other educational materials on biotechnology
and pharmaceutical industries on the transfer
of technology from academia to industry
This recommendation directly links to recommendation 3 given
that the transfer of technology from academia to industry implic-
itly includes intellectual property rights as part of the process.
However, the other key components including the sharing of
techniques, know-how, methodologies, and materials are all
vital to the success of moving a discovery in the laboratory to
a commercial partner for future exploitation. Again, a series of
ongoing workshops and training sessions involving all the rele-
vant stakeholders would greatly facilitate the flow of knowledge
from the laboratory into the commercial realm where it can be
utilized for the benefit of patients and industry. These workshops
would require input from a large number of diverse professionals
including university business units, industrialists, clinicians, law-
yers, patent agents, venture capitalists, and funding agencies.
Indeed, one of the key challenges is to identify all the appropriate
parties in order to provide the necessary comprehensive
approach, be it for the transfer of a material, product, applica-
tion, or a service.
Recommendation 5: Provide public informational
services on global stem cell clinical trials and provide
checklist of questions for patients to ask about clinical
trials so they can make informed choices
The risks and potential harm of unproven stem cell-based thera-
pies are a constant concern to the stem cell research community
(Weissman, 2009) and a potential threat to the establishment of
an ethical, competitive, and sustainable new healthcare sector.
Recommendation 5 is aimed at the complex issue of stem cell
tourism and the need to integrate it with the existing ISSCR activ-
ities including the ‘‘Guidelines for the Clinical Translation of Stem
Cells’’ (Hyun et al., 2008). This recommendation is therefore
aimed at complementing these initiatives by providing a unique
public information service covering specific global stem cell-
based therapeutic options and providing the necessary structure
for properly informed individual choice. First, the recommenda-
tion is to establish and maintain an up-to-date ISSCR web-
based database containing validated information on stem cell
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would not just be an extension of the excellent U.S. National
Institutes of Health, ClinicalTrials.gov (www.clinicaltrials.gov)
website but a bespoke global cell and tissue-engineering
therapy site aimed at providing appropriate information to
patients, their relatives, and their caregivers. To further assist
patient choice and decision making, the ISSCR could provide
a checklist of the absolutely essential questions for patients to
ask about a specific clinical procedure, the clinician involved,
and the healthcare provider/establishment for informed decision
making. This simple user-friendly checklist could easily be drawn
from the existing ‘‘Patient Handbook on Stem Cell Therapies’’
(Annex 1, Guidelines for the Clinical Translation of Stem Cells)
and then translated into appropriate national languages, posted
up on the ISSCR website, and updated on a regular basis. This
recommendation echoes the concerns expressly stated by the
new ISSCR President, Irving Weissman, both during the panel
session andmore fully in his recent President’s Note (Weissman,
2009).
Recommendation 6: Establish a list of potential experts
in different fields that may be of assistance
to scientists newly involved in translational activities
An area that many researchers find challenging is finding expert
advice with respect to the clinical and commercial translation
of potential stem cell-based products. Because the potential
issues are extremely multidisciplinary and diverse, the ISSCR
could greatly assist by establishing and maintaining a list of
experts that come from all the different fields and that may be
required by the scientist wishing to do excellent science and
for it to have impact on society and healthcare in particular.
For further enhancement of the value of this new resource,
a specific mentoring scheme could also be set up. Finally, for
maximizing the impact and providing the necessary global
coverage, the database will need to be web based and probably
template driven, thus allowing both experts to register their
details and researchers to gain easy access to the relevant infor-
mation. The increasing ease of web-based conferencing and
voice calls over the internet will allow this activity to be truly inter-
national. Overall, this recommendation aims to create the global
knowledge network that has been envisioned by a number of
ISSCR presidents including, for example, Paul Simmons (Sim-
mons, 2007). The recommendation also lends itself to the
production of a regenerative medicine product development
route map thus linking to recommendations 1–4.
Recommendation 7: Provide opportunities
for a coordinated academia/industry voice in areas
of policy development
This final recommendation relates specifically to the area of polit-
ical policy development and the need for a sector-specific voice,
an area already identified by ISSCR presidents and the executive
director (Simmons, 2007; Weissman, 2009; Witty, 2007), as well
as previously discussed at length by the panel session moder-
ator Mason in collaboration with Peter Dunnill (Mason and
Dunnill, 2008b). The opportunity for the ISSCR to provide a coor-
dinated academia/industry voice has great potential and con-
siderable ongoing value to both the ISSCR and industry. This
recommendation had strong support from the panel. Although
the industry is still in its infancy, a pivotal role of the ISSCR could
be to publicly bolster these pioneering companies that lack thecritical mass and specifically resources needed to address the
many external pressures that directly impact them, e.g., present-
ing the press with a balanced picture of progress in the field, thus
avoiding hype and still providing a trusted source of scientific
and translational updates. To quote an earlier comment by
Paul Simmons, ‘‘The long-term promise of stem cell research
is vast, but the immediate barriers of translational research are
unquestionably high. The challenge is therefore to promote
a climate supportive of stem cell research while maintaining real-
istic expectations of potential benefits’’ (Simmons, 2007). The
ISSCR being an independent, nonprofit organization and there-
fore free of commercial bias has a big advantage over industry
associations when presenting information to the press and
public. Furthermore, an international organization has the added
advantage of being able to address global issues in a compre-
hensive and integrated manner including such topics as stem
cell tourism and promoting the international harmonization of
regulations. Through its global membership, the ISSCR is ideally
poised for such cross-border activities (Sipp, 2007). One final
aspect might be the honorary appointment or recognition of
preferred industry spokespersons who the ISSCR could recom-
mend to the press both to react to news stories as they break
and, just as importantly, to act in a proactive manner, thus
helping temper hype and hope. Nurturing the clinical and
commercial translation of stem cells and regenerative medicine
will be a patient process and the ability to articulate a realistic
vision of the future therapies and timelines will undoubtedly
benefit everyone.
Summary
Overall, the panel session exposed researchers to the chal-
lenges and opportunities of translation and commercialization,
thus helping to focus down on a number of key issues. The result
was the emergence of a set of practical recommendations
relating to the present sea-change from basic science and
discovery to translation and onward to the establishment of
a successful and sustainable regenerative medicine healthcare
sector. The timing is highly appropriate for a number of major
reasons including amaturation of the science, increasing interest
by big pharma, easing of political restrictions on U.S. Federal
Funding, and a drive toward healthcare reforms especially in
the dominant healthcare market of North America. Without
doubt, regenerative medicine has a significant role to play in
future healthcare and will impact upon the lives of tens, if not
hundreds of millions of patients, their families, and caregivers.
The ISSCR has consistently identified among its activities the
need for academia and industry together to drive the science
from the bench to the clinic as well as to facilitate a realistic
dialog between researchers and the public (Parson, 2007;
Rooke, 2006; Simmons, 2007; Witty, 2007). The seven recom-
mendations to the ISSCR leadership perfectly align with these
aspirations and provide in the near term the necessary founda-
tions required to meet the growing demands of the future regen-
erative medicine industry. The ISSCR is ideally equipped to add
the promotion of clinical and commercial translation to its range
of existing activities. Its strong leadership and established infra-
structure, reputation, and global reach give the ISSCR the unique
strengths necessary for the successful delivery of these recom-
mendations. Because of its novel living cell-based approach,Cell Stem Cell 5, 379–384, October 2, 2009 ª2009 ISSCR 383
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pharma and biotech and thus needs a unified team of stake-
holders if it is to deliver on its promise. Undoubtedly, these
recommendations are only the very start of the evolving pro-
cess of forging links and building sustainable bridges between
the ISSCR and the commercial regenerative medicine industry.
Absolute success will rest with the ISSCR membership and its
collective willingness to embrace translation and commer-
cialization and the regenerative medicine industry to recip-
rocate. Therefore, the author and the panel very much look
forward to seeing the ISSCR leadership taking the recommenda-
tions forward for the benefit of patients, healthcare providers,
and society in general.
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